Can I read S41467 024 45160 Y on EtoBox?

S41467 024 45160 Y by ubig88w4iu is a document available to read on EtoBox.

What is S41467 024 45160 Y about?

This phase II trial evaluated the efficacy and safety of the anti-PD-L1/CTLA-4 bispecific antibody KN046 combined with nab-paclitaxel for first-line treatment of metastatic triple-negative breast cancer (TNBC). The study enrolled 27 patients, achieving an overall response rate of 44% and a median progression-free survival of 7.33 months, with manageable toxicity. The results suggest that this combination therapy is promising, particularly for PD-L1 positive patients, warranting further investigation.

Author

ubig88w4iu

Language

EN